Paul Manner, MD
Orthopaedic Surgery · Seattle, WANPI 1518933639
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $29,000 of the $31,082 with a category attached, or 93.3%. Zimmer Biomet accounts for 93.6% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2021 at $20,292 and has fallen 98.7% since, to $267 in 2025.
Across 22 payments — averaging $1412.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Zimmer Biomet$29K
- Conformis, Inc.$2K
- Davol Inc.$267
What the payments were for
- Speaking & faculty fees$29,00093%
- Travel & lodging$6142%
- Food & beverage$1,4685%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Zimmer Biomet | 3 | $29,081 |
| Conformis, Inc. | 18 | $1,734 |
| Davol Inc. | 1 | $267 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VerSys$29,000
- ZMR$20,000
- Trilogy$9,000
- Hip$973
- iTotal, Identity CR$174
- iTotal Identity PS$174
- iTotal Identity Cruciate Retaining Knee Replacement System$150
- iTotal PS$148
How this compares
$31,082 in reported general payments places this provider in the 85th percentile of 495 orthopaedic surgery providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 69 | $676 |
| Hydromorphone Hcl | 15 | $380 |
| Diclofenac Sodium | 31 | $343 |
| Celecoxib | 17 | $300 |
| Tramadol Hcl | 40 | $95 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Seattle
- James PritchettSeattle$6.4M
- James CrutcherSeattle$3.5M
- Keith MayoSeattle$3.1M
- Matthew SaltzmanSeattle$1.8M
- Burt YaszaySeattle$1.3M
- Sean ToomeySeattle$1.2M
- Robert HartSeattle$942K
- Jeffrey RohSeattle$604K
- Michael BrageSeattle$496K
- Daniel SchwartzSeattle$424K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.